Cromos Pharma

Cromos Pharma is an international research organization (CRO) specializing in clinical trials. Find out more by visiting www.cromospharma.com.

Established in 2004, Cromos Pharma provides tailored and effective clinical trial services to support the development of drugs that transform healthcare. It is an international CRO with over 15 years' experience in offering fully integrated services and delivering all aspects of clinical trials in all clinical phases and a range of therapeutic areas. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has strong regional experience in Central and Eastern Europe. Its US base is in Portland, Oregon with additional operations in South Florida and its European HQ is situated in Dublin, Ireland.

03/03/2026

From Protocol Concept to Cost Clarity in Minutes

For biotech executives, early clinical budgeting is not about precision — it’s about direction, speed, and strategic optionality.

Before NDAs, CRO engagement, or lengthy feasibility cycles, you need clarity:

∙ What will this study likely cost?
∙ How does geography shift the budget profile?
∙ How do enrollment speed, monitoring intensity, and duration affect projections?

That’s why we developed the AI-Powered Clinical Trial Budget Calculator.
In minutes, model countries, site count, enrollment targets, monitoring intensity, and study duration — and instantly see how each variable impacts projected costs. Compare scenarios and generate a clean PDF for board or investor discussions.

This is not a quote.
It’s directional intelligence for executive decision-making.

No waiting. No spreadsheets. No commitments.

Explore the calculator here:https://cromospharma.com/expertise/calculator/

03/02/2026

Cromos Pharma is currently seeking a Senior Clinical Research Associate to join our team.

Location: USA

For additional details about this exciting opportunity, please visit our website: https://lnkd.in/dXgi99MH

If you're ready to take the next step in your career with Cromos Pharma, kindly send your CV to cv@cromospharma.com

,

02/26/2026

Ahead of Rare Disease Day on February 28, 2026, one reality stands out: rare diseases are no longer a niche in pharma.

With half of 2025 FDA approvals carrying orphan designation and pricing, regulatory and access pressures intensifying, rare disease programs are redefining how pharmaceutical value is created.

What does this shift mean for strategy in 2026? Read the full analysis here: https://cromospharma.com/rare-disease-day-2026-a-new-economic-reality-for-pharma/?preview_id=11286&preview_nonce=9bb5e4a24d&_thumbnail_id=11287&preview=true

02/19/2026

The FDA’s rejection of Regenxbio’s gene therapy for Hunter syndrome is more than a single setback. It signals a shift in regulatory expectations for the entire AAV field.

Durability. Clinically meaningful endpoints. Manufacturing robustness. The bar is rising and regulatory risk now weighs as heavily as scientific risk.

What does this mean for gene therapy sponsors and biotech leaders? Read more: https://cromospharma.com/fda-rejects-regenxbio-s-hunter-syndrome-gene-therapy-a-turning-point-for-the-aav-field/?preview_id=11222&preview_nonce=897a022f41&_thumbnail_id=11224&preview=true

02/17/2026

Happy Year of the Horse!

Wishing you a year filled with strength, momentum, and bold achievements. May this lunar cycle bring dynamic growth, new opportunities, and continued success in everything you do.

02/10/2026

SCOPE 2026 made one thing clear: clinical research is moving from experimentation to ex*****on.

From digital protocols and production-ready AI to real site enablement and continuous patient recruitment, the industry is no longer asking if change is coming, but how fast it can scale.

In this article, Nicole Brenna, US Business Development Director at Cromos Pharma, shares key takeaways from SCOPE 2026 and explains how these shifts are already reshaping trial design, operations, and decision-making across sponsors and CROs.

Read the full article here: https://cromospharma.com/why-scope-2026-felt-different-for-clinical-research/?preview_id=11125&preview_nonce=3af800ffd7&_thumbnail_id=11127&preview=true

02/05/2026

Cromos Pharma is on the ground at SCOPE 2026.

Our Business Development Director, Nicole Brenna, is representing Cromos Pharma in Orlando this week meeting with sponsors, reconnecting with partners, and engaging in meaningful conversations about where clinical development is heading next.

SCOPE is always about more than trends. It is about ex*****on, accountability, and what truly works in clinical trials.

If you are here too, let’s connect:inquiry@cromospharma.com

02/04/2026

On World Cancer Day, the focus shifts from what may be possible to what is already making a difference for patients.

In the final part of our Cancer Vaccines series, we look at where cancer vaccines are delivering real clinical impact today from proven prevention strategies to carefully defined therapeutic roles in oncology.

Learn more: https://cromospharma.com/world-cancer-day-2026-what-cancer-vaccines-have-already-achieved-in-real-clinical-practice/

02/02/2026

In the latest edition of Cromos Pharma’s Newsletter, we highlight key developments shaping clinical research in 2026:

– After JPM 2026: CEO Vlad Bogin, MD, FACP, examines where healthcare capital is moving and why ex*****on quality now matters more than ambition.
– NIH Policy Shift: The NIH moves away from human fetal tissue research, prioritizing next-generation models such as organoids and iPSC-based systems.
– AI Regulation: The EMA and FDA align on shared principles for the use of AI across the drug development lifecycle.

Read the full newsletter: https://cromospharma.com/clinical-research-focus-49th-edition/

01/28/2026

JPM 2026 wasn’t about recovery, it was about recalibration.

In this CEO perspective, Vlad Bogin, MD, FACP, breaks down the signals that truly mattered at the J.P. Morgan Healthcare Conference 2026: where capital is concentrating, how AI and GLP-1 strategies are shifting from hype to ex*****on, why oncology is becoming platform-driven, and what this new discipline means for clinical development partners.

A clear-eyed look at how durable growth is being built in healthcare: https://cromospharma.com/after-jpm-2026-where-healthcare-strategy-is-actually-heading/

h

01/26/2026

We’re pleased to share that Nicole Brenna, U.S. Business Development Director at Cromos Pharma, will be attending SCOPE Summit 2026, taking place February 2–5, 2026, in Orlando, FL.

Now in its 17th year, SCOPE Summit is a leading global forum for clinical research, bringing together experts in clinical operations, innovation, data, digital health, and patient engagement to shape the future of clinical development.

Nicole looks forward to connecting with industry peers, exchanging insights, and discussing how Cromos Pharma can support sponsors’ clinical development programs.

If you’ll be attending SCOPE 2026 and would like to schedule a meeting, please reach out to inquiry@cromospharma.com.

01/22/2026

Clinical research in 2026 isn’t slowing down, it’s becoming far more selective.

Capital concentration, regulatory volatility, AI-driven decision-making, and geopolitical complexity are reshaping how trials are designed, funded, and executed. Ex*****on quality now directly impacts asset value, while risk is moving earlier — into feasibility, endpoints, and trial architecture.

In this article, we explore what has fundamentally changed in clinical research, and why resilience, predictability, and confidence are becoming core design requirements for modern clinical programs.

Read more: https://cromospharma.com/clinical-research-in-2026-what-changed-and-why-it-matters/

Address

US Bancorp Tower, 111 S. W. Fifth Avenue, Suite 3150
Portland, OR
97204

Telephone

+15034443463

Website

http://www.cromospharma.com/

Alerts

Be the first to know and let us send you an email when Cromos Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your practice to be the top-listed Clinic in Portland?